Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082128 | 0.78 | MCL1 (0.54) | MC4RKMT2AMEN1MTNR1AMCL1 | |
| SCHEMBL13725011 | 0.77 | MC4R (0.47) | MC4RKMT2AMEN1MTNR1AMCL1 | |
| SCHEMBL3072138 | 0.77 | MC4R (0.65) | MC4R | |
| SCHEMBL3095690 | 0.76 | KDM4E (0.48) | MC4RKMT2AMEN1 | |
| SCHEMBL13723873 | 0.75 | MC4R (0.55) | MC4RKMT2AHPGD | |
| SCHEMBL3093411 | 0.74 | MC4R (0.72) | MC4R | |
| SCHEMBL3095697 | 0.72 | MC4R (0.65) | MC4R | |
| SCHEMBL13147506 | 0.72 | ALDH1A1 (0.61) | KMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL16559363 | 0.65 | ALB (0.49) | KMT2AMEN1HPGD | |
| SCHEMBL11186472 | 0.65 | NR4A1 (0.63) | KMT2AMEN1MTNR1AMCL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1590338-B1 | MODULATORS OF MELANOCORTIN RECEPTOR | ORE PHARMACEUTICALS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1590338-B1 | MODULATORS OF MELANOCORTIN RECEPTOR | ORE PHARMACEUTICALS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1590338-A2 | MODULATORS OF MELANOCORTIN RECEPTOR | Gene Logic Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040147746-A1 | Modulators of melanocortin receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004050610-A2 | MODULATORS OF MELANOCORTIN RECEPTOR | GENE LOGIC INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293498-A1 | Modulators of melanocortin receptor | MC4R, MC1R, MC5R | MC4R 1/4885KMT2A 1522/4885MEN1 566/4885 |
| US-20040147746-A1 | Modulators of melanocortin receptor | MC1R, MC3R, MC5R | MC4R 4/4885KMT2A 1072/4885MEN1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.